These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17934084)

  • 1. The use of the tumour necrosis factor antagonist infliximab in heart transplant recipients: two case reports.
    Metyas S; La D; Arkfeld DG
    Ann Rheum Dis; 2007 Nov; 66(11):1544-5. PubMed ID: 17934084
    [No Abstract]   [Full Text] [Related]  

  • 2. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab).
    Li Gobbi F; Benucci M; Del Rosso A
    J Clin Rheumatol; 2005 Apr; 11(2):119-20. PubMed ID: 16357717
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumour necrosis factor blockade in rheumatoid arthritis.
    Breedveld FC
    Clin Med (Lond); 2001; 1(2):107-9. PubMed ID: 11333452
    [No Abstract]   [Full Text] [Related]  

  • 4. Polymyositis associated with infliximab treatment for rheumatoid arthritis.
    Urata Y; Wakai Y; Kowatari K; Nitobe T; Mizushima Y
    Mod Rheumatol; 2006; 16(6):410-1. PubMed ID: 17165006
    [No Abstract]   [Full Text] [Related]  

  • 5. Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab.
    Hrycaj P; Korczowska I; Łacki JK
    Rheumatology (Oxford); 2003 May; 42(5):702-3. PubMed ID: 12709557
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.
    Hyrich KL; Silman AJ; Watson KD; Symmons DP
    Ann Rheum Dis; 2004 Dec; 63(12):1538-43. PubMed ID: 15242866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis.
    Jiménez FG; Colmenero JD; Irigoyen MV
    J Infect; 2005 May; 50(4):370-1. PubMed ID: 15845443
    [No Abstract]   [Full Text] [Related]  

  • 8. Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.
    Vandevyvere K; Luyten FP; Verschueren P; Lories R; Segaert S; Westhovens R
    Clin Rheumatol; 2007 Dec; 26(12):2205-2206. PubMed ID: 17876646
    [No Abstract]   [Full Text] [Related]  

  • 9. Worsening of obstructive sleep apnoeas in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor.
    Zamarrón C; Maceiras F; González J; Gómez-Reino JJ
    Respir Med; 2004 Feb; 98(2):123-5. PubMed ID: 14971874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Segmental vitiligo after infliximab use for rheumatoid arthritis--a case report.
    Carvalho CL; Ortigosa LC
    An Bras Dermatol; 2014; 89(1):154-6. PubMed ID: 24626663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 14. Extraarticular rheumatoid arthritis and drug-induced syndromes: understanding the role of tumor necrosis factor inhibitors.
    Bruyn GA
    J Rheumatol; 2004 Jul; 31(7):1461; author reply 1462. PubMed ID: 15229972
    [No Abstract]   [Full Text] [Related]  

  • 15. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.
    Gilaberte Y; Coscojuela C; Vázquez C; Roselló R; Vera J
    Br J Dermatol; 2007 Feb; 156(2):368-71. PubMed ID: 17223880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK; Siegel JN
    JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract]   [Full Text] [Related]  

  • 17. Adverse events in patients with rheumatoid arthritis treated with infliximab in daily clinical practice.
    Neven N; Vis M; Voskuyl AE; Wolbink GJ; Nurmohamed MT; Dijkmans BA; Lems WF
    Ann Rheum Dis; 2005 Apr; 64(4):645-6. PubMed ID: 15769924
    [No Abstract]   [Full Text] [Related]  

  • 18. [TNF inhibitors for treatment of rheumatoid arthritis].
    Otomo K; Koike T
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2405-12. PubMed ID: 19149036
    [No Abstract]   [Full Text] [Related]  

  • 19. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
    Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.